Stallergenes revenue up but wary of recession
France-based drugmaker Stallergenes has reported a strong growth in revenue for the first quarter, but is still wary of the future in a turbulent market.
Year-on-year sales growth of 15% was reported for first-quarter 2009 to 56.2 million euros ($74.8 million). Foreign exchange effects were only slightly unfavorable by 0.6%. The firm says growth was mainly from the launch of Oralair in Germany and the transfer of Swiss operations from a distributor to a subsidiary.
Turnover in southern Europe - including Portugal, Spain, France, Italy and Greece - was up 10% to 41.8 million euros. Elsewhere in the European Union, including Switzerland, sales increased 36% to 12.7 million euros. Other markets were flat at 1.7 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze